We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Endobronchial Valves Significantly Improve Emphysema

By HospiMedica staff writers
Posted on 24 Sep 2007
A new study has found that an implantable endobronchial valve significantly improves lung function measures and quality of life for patients with emphysema. More...


The International Endobronchial Valve for Emphysema PalliatioN Trial (VENT) was conducted between December 2004 and April 2006, involving 321 patients with severe heterogeneous emphysema in 31 centers across the United States and Europe. The patients were randomly assigned to the treatment group or a control group in a 2:1 ratio. Primary study endpoints were forced expiratory volume in 1 second [FEV1] and the 6-minute walk test, evaluated at 6 months after treatment.

The study findings showed that among the 220 treated patients who received valve placements, FEV1 had improved by 5.8%, whereas for the 101 controls, FEV1 declined by 0.6%. For the other primary study endpoint, the 6-minute walk test, treated patients improved their distance by 1.7% (about 15 meters) after 6 months, whereas the controls' distance declined by 4.0%. Most secondary endpoints, including quality-of-life scales, also significantly improved. The study results were presented at the 17th Annual Congress of the European Respiratory Society, held during September 2007 in Stockholm (Sweden).

"The underlying logic behind both valve placements and surgical resection is to ‘shrink the footballs' in the chest that do nothing but take up space,” said principal investigator Frank Sciurba, M.D., of the University of Pittsburgh Medical Center (PA, USA). "Inflated, diseased lung saps air from functioning lung and pushes the lungs down too far into the abdomen, where they impair normal mechanical function of the diaphragm.”

The endobronchial valve is designed to block airflow to a diseased region of an emphysematous lung, thereby conferring the benefits of lung volume reduction surgery (LVRS) without the risks of major surgery. The one-way valve allows gas to vent from the isolated lung section during exhalation but prevents air from refilling the area during inhalation. The valve also allows mucus to be expelled, which reduces the chance of infection. Most patients require three valves to be implanted to isolate their most damaged lung section.


Related Links:
University of Pittsburgh Medical Center

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.